

Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

KMS-27

RRID:CVCL_2993

Type: Cell Line

Proper Citation

JCRB Cat# NIHS0488, RRID:CVCL_2993

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2993

Proper Citation: JCRB Cat# NIHS0488, RRID:CVCL_2993

Description: Cell line KMS-27 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Plasma cell myeloma

Defining Citation: [PMID:15215163](#), [PMID:15491288](#), [PMID:17171682](#), [PMID:18700954](#), [PMID:19306352](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:28196595](#), [PMID:30285677](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:32123307](#)

Comments: Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: KMS-27

Synonyms: KMS27, Kawasaki Medical School-27

Cross References: EFO:EFO_0006616, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, BioSample:SAMN03472924, BioSample:SAMN10987819, cancercellines:CVCL_2993, Cell_Model_Passport:SIDM01573, CGH-DB:25-1, CGH-DB:9138-4, Cosmic:2391811, DepMap:ACH-000576, EGA:EGAS00001000610, GEO:GSM143347, GEO:GSM290299, GEO:GSM887226, GEO:GSM888300, IARC_TP53:30104, JCRB:JCRB1188, JCRB:NIHS0488, LiGeA:CCLE_594,

PharmacoDB:KMS27_769_2019, Progenetix:CVCL_2993, Wikidata:Q54900176

ID: CVCL_2993

Vendor: JCRB

Catalog Number: NIHS0488

Record Creation Time: 20220427T220706+0000

Record Last Update: 20260815T234429+0000

Ratings and Alerts

No rating or validation information has been found for KMS-27.

Warning: Discontinued: JCRB; NIHS0488

Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Tiwari PK, et al. (2026) An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma. Cell reports, 45(6), 117464.

Konishi H, et al. (2025) The butyrate derived from probiotic Clostridium butyricum exhibits an inhibitory effect on multiple myeloma through cell death induction. Scientific reports, 15(1), 11919.

Nardone C, et al. (2025) Structural basis for the midnolin-proteasome pathway and its role in suppressing myeloma. Molecular cell, 85(13), 2597.

Oikonomidi I, et al. (2025) Interferon regulatory factor 4 mediates nonenzymatic IRE1 dependency in multiple myeloma cells. PLoS biology, 23(4), e3003096.

Vannam R, et al. (2021) Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. Cell chemical biology, 28(4), 503.

Shirasaki R, et al. (2021) Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degradors of Oncoproteins. Cell reports, 34(1), 108532.